Clinical Trial Detail

NCT ID NCT03960840
Title CD19-specific CAR-T Cells in CLL/SLL and DLBCL
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

CLL/SLL

chronic lymphocytic leukemia

diffuse large B-cell lymphoma

Therapies

Ibrutinib + YTB323

YTB323

Age Groups: adult senior

No variant requirements are available.